1800-272-662
Shopping Cart 0
countryflagAU
Login

60 Degrees Pharmaceuticals, Inc. Common Stock

Healthcare US SXTP

2.1697USD
0.29(15.41%)

Last update at 2026-03-11T15:06:00Z

Day Range

2.002.28
LowHigh

52 Week Range

0.208.65
LowHigh

Fundamentals

  • Previous Close 1.88
  • Market Cap3.31M
  • Volume13071386
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.10426M
  • Revenue TTM0.25M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM -0.44672M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -6.17728M -4.25930M -3.04747M
Minority interest -0.00394M 0.00855M 0.01M
Net income -6.18172M -4.25174M -3.03374M
Selling general administrative 1.30M 1.12M 1.46M
Selling and marketing expenses - - -
Gross profit -0.20916M 0.31M 1.48M
Reconciled depreciation 0.08M 0.07M 0.03M
Ebit -1.79368M -1.08659M -0.36904M
Ebitda -1.71490M -1.01480M -0.34117M
Depreciation and amortization 0.08M 0.07M 0.03M
Non operating income net other - - -
Operating income -1.75045M -1.12410M -0.41813M
Other operating expenses 1.97M 2.28M 2.55M
Interest expense 3.99M 3.17M 2.68M
Tax provision 0.00050M 0.00100M 0.00100M
Interest income - - -
Net interest income -3.98936M -3.17271M -2.67843M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.00050M 0.00100M 0.00100M
Total revenue 0.22M 1.16M 2.18M
Total operating expenses 1.54M 1.43M 1.85M
Cost of revenue 0.43M 0.85M 0.70M
Total other income expense net -0.43748M 0.04M -0.00012M
Discontinued operations - - -
Net income from continuing ops -6.17778M -4.26030M -3.04847M
Net income applicable to common shares -6.18172M -6.18172M -3.03374M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 7.78M 1.30M 1.39M 2.61M
Intangible assets 0.23M 0.16M 0.11M 0.08M
Earning assets - - - -
Other current assets 4.40M 0.20M 0.22M 0.35M
Total liab 2.99M 25.45M 19.55M 20.68M
Total stockholder equity 4.87M -23.57674M -17.57823M -17.50153M
Deferred long term liab - - - -
Other current liab 2.31M 1.69M 0.00313M 0.06M
Common stock 0.00058M 0.00024M 4.98M 0.80M
Capital stock 9.86M 0.00024M 4.98M 0.80M
Retained earnings -32.58085M -28.81515M -22.63343M -18.38168M
Other liab - 0.26M - -
Good will - - - -
Other assets - - - -
Cash 2.14M 0.26M 0.12M 0.19M
Cash and equivalents - - - -
Total current liabilities 2.84M 23.92M 0.64M 1.43M
Current deferred revenue - 0.33M -0.00313M -
Net debt -1.96981M 22.15M 18.69M 15.73M
Short term debt 0.02M 21.15M 0.05M -
Short long term debt 0.00877M 21.14M - -
Short long term debt total 0.17M 22.42M 18.80M 15.92M
Other stockholder equity 27.46M 5.16M - -
Property plant equipment - - 0.11M -
Total current assets 7.24M 1.10M 1.18M 2.44M
Long term investments - - - -
Net tangible assets - -23.74100M -17.68747M -17.58176M
Short term investments - - - -
Net receivables 0.23M 0.05M 0.15M 0.86M
Long term debt 0.15M 1.27M 18.74M 15.92M
Inventory 0.47M 0.52M 0.69M 1.04M
Accounts payable 0.51M 0.76M 0.59M 1.38M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 0.14M 0.07M 0.08M 0.08M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.24M - - 0.00955M
Deferred long term asset charges - - - -
Non current assets total 0.54M 0.20M 0.22M 0.16M
Capital lease obligations 0.01M 0.01M 0.06M 0.00000M
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.06013M -0.03539M -0.07098M
Change to liabilities 0.00000M -0.84467M 0.80M
Total cashflows from investing activities -0.06013M -0.06013M -0.07098M
Net borrowings - 0.61M 0.61M
Total cash from financing activities 1.22M 0.61M 0.28M
Change to operating activities - - -
Net income -6.17778M -4.26030M -3.04847M
Change in cash 0.15M -0.07630M -0.09517M
Begin period cash flow 0.12M 0.19M 0.29M
End period cash flow 0.26M 0.12M 0.19M
Total cash from operating activities -1.00998M -0.64911M -0.16730M
Issuance of capital stock - - -
Depreciation 0.08M 0.07M 0.03M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory -0.05294M 0.31M 0.19M
Change to account receivables 0.10M 0.71M -0.66028M
Sale purchase of stock - - -
Other cashflows from financing activities 1.22M 0.68M 0.43M
Change to netincome 0.62M 0.62M 0.62M
Capital expenditures 0.06M 0.04M 0.07M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 3.31M 2.90M 2.43M
Stock based compensation - - -
Other non cash items 1.78M 0.64M 0.43M
Free cash flow -1.07011M -0.68450M -0.23828M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock		 0.29 15.41% 2.17 - - 12.02 - 43.13 -7.666
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

60 Degrees Pharmaceuticals, Inc. Common Stock

1025 Connecticut Avenue NW, Washington, DC, United States, 20036

Key Executives

Name Title Year Born
Dr. Geoffrey Stuart Dow Chairman, CEO & President 1974
Mr. Tyrone Miller CFO & Treasurer 1975
Dr. Bryan Smith Chief Medical Officer 1966
Ms. Kristen Landon Chief Commercial Officer 1967
Ms. Jennifer Herz Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.